TBPH
NASDAQ · Pharmaceuticals
Theravance Biopharma Inc
$16.58
-0.13 (-0.78%)
Financial Highlights (FY 2026)
Revenue
106.72M
Net Income
105.16M
Gross Margin
100.0%
Profit Margin
98.5%
Rev Growth
+28.0%
D/E Ratio
0.11
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 61.7% | 61.7% |
| Operating Margin | 43.2% | 38.9% | 15.8% | 13.6% |
| Profit Margin | 98.5% | 93.6% | 12.8% | 13.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 106.72M | 83.41M | 591.55M | 658.39M |
| Gross Profit | 106.72M | 83.41M | 364.96M | 406.20M |
| Operating Income | 46.08M | 32.41M | 93.68M | 89.66M |
| Net Income | 105.16M | 73.97M | 75.68M | 89.76M |
| Gross Margin | 100.0% | 100.0% | 61.7% | 61.7% |
| Operating Margin | 43.2% | 38.9% | 15.8% | 13.6% |
| Profit Margin | 98.5% | 93.6% | 12.8% | 13.6% |
| Rev Growth | +28.0% | +28.0% | +8.8% | -5.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 42.53M | 42.53M | 481.91M | 528.63M |
| Total Equity | 384.85M | 384.85M | 471.86M | 413.39M |
| D/E Ratio | 0.11 | 0.11 | 1.02 | 1.28 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 47.69M | 35.41M | 125.32M | 145.74M |
| Free Cash Flow | — | — | 94.80M | 134.21M |